Advertisement
Screener

ELI LILLY AND COMPANY (LLY) ROI

ELI LILLY & Co ROI

Return on investment (ROI), also called return on invested capital, is the profit a company earns for every dollar of long-term capital from both lenders and shareholders, shown as a percentage. It is net income divided by long-term debt plus shareholder equity, and the table shows both amounts. Because debt is included in the base, ROI does not rise just because a company replaces equity with borrowing, which sets it apart from ROE. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • ELI LILLY & Co roi for the quarter ending 2014-03-31 was 15.71%, a 30.67% decline year-over-year.
  • ELI LILLY & Co roi for the quarter ending 2013-12-31 was 20.50%, a 1.80% increase year-over-year.
  • ELI LILLY & Co roi for the quarter ending 2013-09-30 was 21.59%, a 13.09% increase year-over-year.
  • ELI LILLY & Co roi for the quarter ending 2013-06-30 was 23.88%, a 17.47% increase year-over-year.
  • ELI LILLY & Co roi for fiscal 2013 was 20.50%, a 1.80% increase from fiscal 2012.
  • ELI LILLY & Co roi for fiscal 2012 was 20.14%, a 4.95% decline from fiscal 2011.
  • ELI LILLY & Co roi for fiscal 2011 was 21.18%, a 19.18% decline from fiscal 2010.
  • ELI LILLY & Co roi for fiscal 2010 was 26.21%, a 1.98% decline from fiscal 2009.
Available history
2008-12-31 to 2014-03-31
Data captured

Historical ROI

DateROINet income 12 monthNet income 3 monthDebt plus equity
2014-03-3115.71%$3.86B$727.90M$24.6B
2013-12-3120.50%$4.68B$727.50M$22.85B
2013-09-3021.59%$4.78B$1.20B$22.16B
2013-06-3023.88%$4.91B$1.21B$20.55B
2013-03-3122.66%$4.63B$1.55B$20.42B
2012-12-3120.14%$4.09B$827.20M$20.31B
2012-09-3019.09%$4.12B$1.33B$21.58B
2012-06-3020.33%$4.03B$923.60M$19.82B
2012-03-3121.26%$4.3B$1.01B$20.24B
2011-12-3121.18%$4.35B$858.20M$20.52B
2011-09-3021.05%$4.66B$1.24B$22.14B
2011-06-3022.50%$4.73B$1.20B$21.01B
2011-03-3123.67%$4.88B$1.06B$20.61B
2010-12-3126.21%$5.07B$1.17B$19.34B
2010-09-3024.64%$4.82B$1.30B$19.54B
2010-06-3026.01%$4.45B$1.35B$17.12B
2010-03-3124.87%$4.26B$1.25B$17.14B
2009-12-3126.74%$4.33B$915.40M$16.19B
2009-09-30-1.25%-$216M$941.80M$17.3B
2009-06-30-9.97%-$1.62B$1.16B$16.28B

Annual ROI

DateROINet income 12 monthDebt plus equity
2013-12-3120.50%$4.68B$22.85B
2012-12-3120.14%$4.09B$20.31B
2011-12-3121.18%$4.35B$20.52B
2010-12-3126.21%$5.07B$19.34B
2009-12-3126.74%$4.33B$16.19B
2008-12-31-12.05%-$2.07B$17.2B

Similar stocks

Stock NameCountryMarket CapPE Ratio
Akari Therapeutics Plc (AKTX)$1,527.991B-47,921.42
JOHNSON & JOHNSON (JNJ)United States$652.528B29.10
AbbVie Inc. (ABBV)United States$468.180B70.37
Merck & Co., Inc. (MRK)United States$365.215B99.96
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
PFIZER INC (PFE)United States$162.042B31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94